- Facilitators of Innovation
- New in My Practice: Cosmeceuticals
- New Products
- New in My Practice: Devices
- Acne-Related PIH
- Collaborative Relationships Inspire Innovation: Keys to Practice Growth
- Negotiating With Vendors
- Going Social: A Social Media Primer for Aesthetic Practitioners
- Managing Online Reputation for Cosmetic Surgeons
- Evidence of emerging innovation in medical aesthetics.
- The Next Big Thing: How To Spot It and Avoid the Imitators
- If You Want to Innovate, Think Delegate
- The Aesthetic Patient: Communication and Education Remain the Cornerstone of Cosmetic Procedures
- 5 Perspectives on Innovation
- Editorial Board Forum: Is Innovation Important in Practice?
- New Insights into Neurotoxins
- Taking the Pulse of Hydroquinone Therapy: A Plea for Caution
- Emerging Innovations in Aesthetics
- Meeting Notes
- News & Trends
News from recent meetings, and a guide to upcoming events.
Pipeline Watch: Investigational Injectable Found Safe, Eff ective for Submental Fat
An investigational injectable drug for the reduction of submental fat, ATX-101 from Kythera Biopharmaceuticals was found both safe and effective according to new data presented at the AAD Annual Meeting in Miami in March. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment showed that 87 percent of patients achieved at least a one-grade improvement from baseline on the Clinician-Reported Submental Fat Rating Scale. Similarly, 83 percent of patients achieved at least a one-grade improvement on the Patient-Reported Submental Fat Rating Scale. In addition, 96 percent of patients had unchanged or improved skin laxity based on the clinician rated Submental Skin Laxity Grading Scale, while 95 percent of patients were satisfied with treatment based on the Global Post Treatment Satisfaction Scale. Adverse events seen in the trial were of mild to moderate intensity, transient, and primarily associated with the treatment area.
Technology Watch: Modernizing Medicine Unveils Next Stage of EHR Innovation
Compiling disease-specific data at the point of care is the latest development for Modernizing Medicine’s Electronic Medical Assistant (EMA) EHR technology, as noted by Michael Sherling, MD, co-founder and chief medical officer of Modernizing Medicine, at the AAD Meeting in Miami, FL. “EMA provides user data on various dermatologic conditions and aesthetic procedures, allowing clinicians to see what their colleagues are prescribing/performing in specific disease cases,” observed Dr. Sherling. Powering this data to the clinician in practice is extremely valuable, he continued, as it offers unprecedented engagement and connection with their colleagues. Clinicians can thus learn more about specific combinations and other details regarding disease-drug interaction on a wider scale.
Optimizing Clinical Success: Don’t Fear Deviating from the Traditional
Focus on modulating all of the biochemical mechanisms that produce the visible skin condition the patient is concerned about, said Carl Thornfeldt, MD at the Fourth Annual Cosmetic Surgery Forum in Las Vegas, NV. According to Dr. Thornfeldt, most cutaneous conditions (including photoaging) result from abnormalities of multiple biochemical pathways. When clinicians repair the underlying anomalies, the best clinical results occur, he noted. “Do not fear deviating from traditional paradigms to create the best treatment regimen for your patient,” he advised.
Mastering the Business of Aesthetics
April 20, 2013
New York, NY
June 20-23, 2013
Vegas Cosmetic Surgery 2013
June 26-30, 2013
Las Vegas, NV
2013 ASDS Annual Meeting
October 3-6, 2013
Plastic Surgery 2013
October 11-15, 2013
San Diego, CA
Cosmetic Surgery Forum 2013
December 5-7, 2013
Las Vegas, NV